Alnylam amyloidosis drug led to “small” benefits: FDA

The U.S. Meals and Drug Administration (FDA) mentioned Monday that patisiran, a RNAi therapeutic developed by Alnylam Prescribed drugs (NASDAQ:ALNY) for amyloidosis, induced solely a “small” scientific profit in a Part 3 trial.

The FDA’s views got here in briefing paperwork launched forward of an advisory committee assembly on Alnylam’s (ALNY) supplemental New Drug Utility (sNDA) for patisiran focused at cardiomyopathy (CM) linked to the uncommon dysfunction transthyretin-mediated (ATTR) amyloidosis.

The assembly of the regulator’s Cardiovascular and Renal Medicine Advisory Committee is predicted to happen on September 13.

“The pivotal trial for patisiran for ATTR-cardiomyopathy demonstrated statistically important advantages of small magnitude,” the FDA reviewers wrote concerning the drug, a possible rival to Pfizer’s (PFE) amyloidosis remedy Vyndamax.

The FDA famous that patisiran, already out there within the U.S. as Onpattro to deal with adults with polyneuropathy linked to hereditary ATTR amyloidosis, confirmed no main security occasions.

Nonetheless, “a constructive benefit-risk profile can’t be concluded if there isn’t a significant good thing about the remedy to sufferers in how they really feel, operate, or survive,” the staffers added.

The views of AdCom panelists are non-binding for the FDA, which is predicted to resolve on Alnylam’s sNDA on or earlier than October 8, 2023.